BENZODIAZEPINES AND HYPNOTIC ANTIPSYCHOTICS IN A PSYCHIATRIC HOSPITAL
5PSQ-040
PHARMACEUTICALS IN HOSPITAL WASTEWATER: A REVIEW
5PSQ-031
EVALUATION OF THE SAFETY AND TOLERANCE OF THE COMMERCIAL PRESENTATION OF CICLOSPORINE 0.1% COLLYRIUM
5PSQ-029
EVALUATION OF THE EFFICACY AND SAFETY OF ERENUMAB IN THE PROFILAXIS OF CHRONIC AND EPISODIC MIGRAINE
5PSQ-023
Neutropenia as an indicator of trifluridinetipiracil efficacy in metastatic colorectal cancer
5PSQ-022
DESENSITISATION PROTOCOL FOR ADALIMUMAB IN ARTHROPATHIC PSORIASIS: A CASE REPORT
5PSQ-021
Patient´s and physician´s acceptance of a pharmacist-led intervention to reduce anticholinergic burden
5PSQ-019
ASSESSMENT OF THE LEVEL OF KNOWLEDGE AND MOTIVATION IN A HOSPITAL CENTER STAFF FOR GETTING VACCINATED AGAINST SARS-CoV-2
5PSQ-018
ANALYSIS OF THE USE OF FONDAPARINUX IN SUSPECTED HEPARIN-INDUCED THROMBOCYTOPENIA
5PSQ-015
ANTIBIOTIC DESENSITIZATION IN PATIENTS WHO WERE PREVIOUSLY TREATED WITH POTENTIALLY ALLERGY-TRIGGERING MOLECULES
5PSQ-014
SAFETY AND TOLERANCE PROFILE OF NIVOLUMAB AND PEMBROLIZUMAB
5PSQ-013
ANTINEOPLASTIC DRUGS AND THROMBOSIS: ANALYSIS OF A COHORT OF PATIENTS WITH CANCER-ASSOCIATED THROMBOSIS
5PSQ-012
ARE 12 MONTHS OF TREATMENT WITH MONOCLONAL ANTIBODIES SUFFICIENT FOR MIGRAINE ATTACK PREVENTION?
5PSQ-002
ADVERSE EVENTS REPORTED AFTER ADMINISTRATION OF BNT162B2 AND MRNA-1273 COVID-19 VACCINES AMONG HEALTHCARE-WORKERS
5PSQ-145
ANALYSIS OF THERAPEUTIC REGIMENS CONTAINING TENOFOVIR DISOPROXIL AND TENOFOVIR ALAFENAMIDE IN THE 4 YEAR PERIOD 2016-2019 IN A RESEARCH, HOSPITALISATION AND HEALTHCARE INSTITUTE
